Drug intelligence / Profile preview

taxane + bevacizumab + capecitabine

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination therapy regimen consisting of a taxane (a class of chemotherapy drugs), bevacizumab (a monoclonal antibody that inhibits angiogenesis), and capecitabine (an oral chemotherapy drug). This combination is used in the treatment of metastatic breast cancer. Bevacizumab works by inhibiting vascular endothelial growth factor A (VEGF-A), thereby slowing the growth of new blood vessels. Capecitabine is an oral chemotherapeutic agent, and taxanes are a class of chemotherapy drugs that disrupt microtubule function.

Targets

VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)

Beyond the preview

Go deeper on taxane + bevacizumab + capecitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on taxane + bevacizumab + capecitabine.

Explore the full profile